View in EDS HTML Full Text

Huntington's Hopes.

Saved in:
Bibliographic Details
Title: Huntington's Hopes.
Authors: Parshall, Allison (AUTHOR)
Source: Scientific American. Jan2026, Vol. 334 Issue 1, p8-11. 4p. 1 Color Photograph.
Subjects: Huntington disease, Gene therapy, Clinical trials, Disease progression, Brain surgery, Health services accessibility, Drug approval
Abstract: The article discusses the promising results of AMT-130, an experimental gene therapy for Huntington's disease, which appears to slow disease progression. Conducted by uniQure, the phase ½ clinical trials involved 24 participants and indicated that a high dose of AMT-130 reduced the rate of progression by 75% compared to an external control group. The treatment requires invasive brain surgery to deliver the drug directly into affected neurons and aims for FDA accelerated approval by the end of 2026. While this development offers hope to the Huntington's community, concerns remain regarding the treatment's cost and accessibility. [Extracted from the article]
Copyright of Scientific American is the property of Scientific American and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
Full text is not displayed to guests.
FullText Text:
  Availability: 1
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 189782883
AccessLevel: 6
PubType: Periodical
PubTypeId: serialPeriodical
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Huntington's Hopes.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Parshall%2C+Allison%22">Parshall, Allison</searchLink> (AUTHOR)
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Scientific+American%22">Scientific American</searchLink>. Jan2026, Vol. 334 Issue 1, p8-11. 4p. 1 Color Photograph.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Huntington+disease%22">Huntington disease</searchLink><br /><searchLink fieldCode="DE" term="%22Gene+therapy%22">Gene therapy</searchLink><br /><searchLink fieldCode="DE" term="%22Clinical+trials%22">Clinical trials</searchLink><br /><searchLink fieldCode="DE" term="%22Disease+progression%22">Disease progression</searchLink><br /><searchLink fieldCode="DE" term="%22Brain+surgery%22">Brain surgery</searchLink><br /><searchLink fieldCode="DE" term="%22Health+services+accessibility%22">Health services accessibility</searchLink><br /><searchLink fieldCode="DE" term="%22Drug+approval%22">Drug approval</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: The article discusses the promising results of AMT-130, an experimental gene therapy for Huntington's disease, which appears to slow disease progression. Conducted by uniQure, the phase ½ clinical trials involved 24 participants and indicated that a high dose of AMT-130 reduced the rate of progression by 75% compared to an external control group. The treatment requires invasive brain surgery to deliver the drug directly into affected neurons and aims for FDA accelerated approval by the end of 2026. While this development offers hope to the Huntington's community, concerns remain regarding the treatment's cost and accessibility. [Extracted from the article]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of Scientific American is the property of Scientific American and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=189782883
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1038/scientificamerican012026-5rsmeajbz76o5mligkrnvl
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 4
        StartPage: 8
    Subjects:
      – SubjectFull: Huntington disease
        Type: general
      – SubjectFull: Gene therapy
        Type: general
      – SubjectFull: Clinical trials
        Type: general
      – SubjectFull: Disease progression
        Type: general
      – SubjectFull: Brain surgery
        Type: general
      – SubjectFull: Health services accessibility
        Type: general
      – SubjectFull: Drug approval
        Type: general
    Titles:
      – TitleFull: Huntington's Hopes.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Parshall, Allison
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 01
              Text: Jan2026
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-print
              Value: 00368733
          Numbering:
            – Type: volume
              Value: 334
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Scientific American
              Type: main
ResultId 1